research Archives - Page 4 of 9

Home
/
Projects
/

research

Perceptions of the incarcerated population regarding tuberculosis research and vaccines

A qualitative study that aims to understand to perceptions and attitudes regarding TB, TB vaccines, and participation in TB vaccine trials among persons deprived of liberty (PDR) in Brazil.

Navigating the unknown: Ensuring equitable TB vaccine access to maximize health impact

2024

A scoping literature review is underway to identify key principles and strategies from existing vaccine allocation frameworks. The review focuses on vaccines utilized in routine and emergency contexts, including malaria, COVID-19, dengue, and meningococcal vaccines, among others.

Potential implications of reduced tuberculosis vaccine efficacy in those with undernutrition on overall vaccine impact in India

Hypothetical vaccines

Nutritional status is a leading risk factor for tuberculosis (TB). In India up to half of all TB episodes are attributed to undernutrition. Given the impact of nutrition on the immune system, vaccine characteristics such as efficacy and duration of protection could vary depending on nutritional status. Therefore, previous vaccine impact estimates may be overestimated. We re estimated vaccine impact in India with reduced efficacy with undernutrition

Evolution of Tuberculosis Vaccine Modelling studies: Insights from studies in India

Focusing on India, we performed a scoping review to identify and evaluate studies that have used mathematical modeling to assess the epidemiological and economic impact of TB vaccine introduction in India

Enhancing community engagement in tuberculosis vaccine delivery among key populations: A qualitative study

This qualitative study investigated methods to enhance community engagement in TB vaccine delivery among Men Who Have Sex with Men.

Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan

Our study assessed the willingness of pregnant women across four countries - Brazil, Ghana, Kenya, and Pakistan to receive a future TB vaccine.

The implications of using different time horizons when evaluating investment to prevent infectious disease

Hypothetical vaccines

A lifetime time horizon is conventional for cost-effectiveness analysis, but not routine for transmission-dynamic modeling, given uncertainty in future epidemiological dynamics and high computation costs. We demonstrate implications of alternative analytic time horizons with a case study of novel tuberculosis (TB) vaccine introduction

IGRA prevalence study

2024-2025

A cross-sectional study to determine IGRA positivity rate to assess eligibility for participation in tuberculosis (TB) vaccine efficacy trials

Insights into TB vaccine acceptability among adolescents in Khayelitsha through community engagement

Initially designed as an internal assessment of the impact of engagement workshops, we used short surveys to understand high-school learner perspectives of vaccines, focusing on COVID 19, TB and HIV vaccines. Between 2022 and 2024, we collected responses from 350 adolescents (14-18 years old). All participants live in Khayelitsha, where high rates of TB (4224 cases notified in the last year) intersect with socio-economic challenges

Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV

2023-2024

Hypothetical vaccines

This project will inform tuberculosis (TB) prevention efforts by estimating the health impact of novel tuberculosis vaccines on TB burden in people living with HIV (PLHIV) using a novel Mycobacterium tuberculosis transmission model. HIV confers the largest relative risk of TB, and new TB vaccines could be an important tool to prevent TB; however, modelling studies have not systematically investigated how new vaccines will affect TB burden in PLHIV. In stage 1 of this project, we aim to investigate TB vaccine impact in PLHIV where vaccine product characteristics and delivery vary by recipient HIV status. In stage 2, we aim to quantify how complex vaccine targeting strategies and incorporating additional granularity in HIV/AIDS natural history might affect vaccine impact estimates in PLHIV